To accelerate the dissemination and implementation of new evidence-based practices for T2D into primary care settings, MCT2D selected three initial evidence-based quality improvement (QI) initiatives that are often underutilized yet highly effective for improving outcomes for patients with T2D: (1) guideline-directed use of pharmacotherapy to improve cardiorenal outcomes, including appropriate prescribing of SGLT2i and GLP-1 RA medications, (2) evidence-based use of continuous glucose monitoring (CGM), and (3) lower carbohydrate eating patterns [Fig. 1]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.